---
title: "Investing in Innovation (i3)"
description: "Investing in Innovation (i3) is a health tech focused grant program that provides financial and technical support to early stage companies. It operates through the Investing in Innovation initiative, which offers structured grant funding for selected innovators in the healthcare and pharmaceutical value chain. A public contact for the program is listed via the Investing in Innovation website. In Africa, Investing in Innovation (i3) has provided grant funding to health tech companies in multiple markets. According to available investment records, the program has deployed 800,000 dollars across four grant rounds in April 2025, all at the grant stage. The program has backed RxAll in Nigeria, Meditect in Côte d'Ivoire, Dawa Mkononi in Tanzania, and Chefaa in Egypt, reflecting a focus on technology enabled solutions for medicine authentication, pharmacy management, credit for health facilities, and pharmacy delivery. These investments indicate a geographic focus that spans West, East, and North Africa within the health tech sector. Publicly available information also indicates that Investing in Innovation (i3) accepts applications from health tech innovators seeking grants and support, suggesting a structured intake process for new cohorts. The initiative positions itself around supporting scalable health technology solutions, particularly those improving access to quality medicines and strengthening pharmaceutical systems in African markets."
canonical_url: "https://liners.com/investors/investing-in-innovation-i3"
markdown_url: "https://liners.com/investors/investing-in-innovation-i3.md"
type: "investor"
language: "en"
updated_at: "2026-07-22T03:01:45.299Z"
---

# Investing in Innovation (i3)

Investing in Innovation (i3) is a health tech focused grant program that provides financial and technical support to early stage companies. It operates through the Investing in Innovation initiative, which offers structured grant funding for selected innovators in the healthcare and pharmaceutical value chain. A public contact for the program is listed via the Investing in Innovation website. In Africa, Investing in Innovation (i3) has provided grant funding to health tech companies in multiple markets. According to available investment records, the program has deployed 800,000 dollars across four grant rounds in April 2025, all at the grant stage. The program has backed RxAll in Nigeria, Meditect in Côte d'Ivoire, Dawa Mkononi in Tanzania, and Chefaa in Egypt, reflecting a focus on technology enabled solutions for medicine authentication, pharmacy management, credit for health facilities, and pharmacy delivery. These investments indicate a geographic focus that spans West, East, and North Africa within the health tech sector. Publicly available information also indicates that Investing in Innovation (i3) accepts applications from health tech innovators seeking grants and support, suggesting a structured intake process for new cohorts. The initiative positions itself around supporting scalable health technology solutions, particularly those improving access to quality medicines and strengthening pharmaceutical systems in African markets.

## Breadcrumbs

- [Investors](/investors)
- [Investing in Innovation (i3)](/investors/investing-in-innovation-i3)

## Summary

Investing in Innovation (i3) is a health tech focused grant program that provides financial and technical support to early stage companies. It operates through the Investing in Innovation initiative, which offers structured grant funding for selected innovators in the healthcare and pharmaceutical value chain. A public contact for the program is listed via the Investing in Innovation website. In Africa, Investing in Innovation (i3) has provided grant funding to health tech companies in multiple markets. According to available investment records, the program has deployed 800,000 dollars across four grant rounds in April 2025, all at the grant stage. The program has backed RxAll in Nigeria, Meditect in Côte d'Ivoire, Dawa Mkononi in Tanzania, and Chefaa in Egypt, reflecting a focus on technology enabled solutions for medicine authentication, pharmacy management, credit for health facilities, and pharmacy delivery. These investments indicate a geographic focus that spans West, East, and North Africa within the health tech sector. Publicly available information also indicates that Investing in Innovation (i3) accepts applications from health tech innovators seeking grants and support, suggesting a structured intake process for new cohorts. The initiative positions itself around supporting scalable health technology solutions, particularly those improving access to quality medicines and strengthening pharmaceutical systems in African markets.

## Recorded investments

| Product | URL | Stage | Amount | Date |
| --- | --- | --- | --- | --- |
| RxAll | /rxall | Grant | 200000 | 2025-04-01T00:00:00.000Z |
| Meditect | /meditect | Grant | 200000 | 2025-04-01T00:00:00.000Z |
| Dawa Mkononi | /dawa-mkononi | Grant | 200000 | 2025-04-01T00:00:00.000Z |
| Chefaa | /chefaa | Grant | 200000 | 2025-04-01T00:00:00.000Z |

## Related pages

- [All investors](/investors)
- [Funding rounds](/funding)

## Access and citation

- [Canonical HTML page](https://liners.com/investors/investing-in-innovation-i3)
- [Markdown route index](/sitemap.md)
- [Agent access guide](/llms.txt)